Home >> Oncology/Hematology >> Oncology/Hematology >> Baked Goods >> Technology & Media >>

Febrile Neutropenia - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 51 | Code: MRS - 18263

Febrile Neutropenia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Febrile Neutropenia - Pipeline Review, H1 2015’, provides an overview of the Febrile Neutropenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Febrile Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Febrile Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Febrile Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Febrile Neutropenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Febrile Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Febrile Neutropenia Overview 7
Therapeutics Development 8
Pipeline Products for Febrile Neutropenia - Overview 8
Pipeline Products for Febrile Neutropenia - Comparative Analysis 9
Febrile Neutropenia - Therapeutics under Development by Companies 10
Febrile Neutropenia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Febrile Neutropenia - Products under Development by Companies 14
Febrile Neutropenia - Companies Involved in Therapeutics Development 15
Apotex, Inc. 15
Biocon Limited 16
Coherus BioSciences, Inc. 17
Pfizer Inc. 18
Richter Gedeon Nyrt. 19
Sandoz International GmbH 20
Teva Pharmaceutical Industries Limited 21
Therapeutic Proteins International, LLC 22
Xenetic Biosciences plc 23
Febrile Neutropenia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(piperacillin sodium + tazobactam sodium) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
filgrastim - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
filgrastim - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
filgrastim (recombinant) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
lipegfilgrastim - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pegfilgrastim - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pegfilgrastim - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pegfilgrastim - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pegfilgrastim - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pegfilgrastim - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pegfilgrastim - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Stimuxen - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Febrile Neutropenia - Recent Pipeline Updates 47
Febrile Neutropenia - Product Development Milestones 48
Featured News & Press Releases 48
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 48
Jul 02, 2014: Application for the Additional Indication of Febrile Neutropenia for ZOSYN, an Injectable Antibiotic Combined with ß-Lactamase Inhibitor 48
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables
Number of Products under Development for Febrile Neutropenia, H1 2015 8
Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Febrile Neutropenia - Pipeline by Apotex, Inc., H1 2015 15
Febrile Neutropenia - Pipeline by Biocon Limited, H1 2015 16
Febrile Neutropenia - Pipeline by Coherus BioSciences, Inc., H1 2015 17
Febrile Neutropenia - Pipeline by Pfizer Inc., H1 2015 18
Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2015 19
Febrile Neutropenia - Pipeline by Sandoz International GmbH, H1 2015 20
Febrile Neutropenia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 21
Febrile Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H1 2015 22
Febrile Neutropenia - Pipeline by Xenetic Biosciences plc, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Assessment by Combination Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Febrile Neutropenia Therapeutics - Recent Pipeline Updates, H1 2015 47

List of Figures
Number of Products under Development for Febrile Neutropenia, H1 2015 8
Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing